title: Expression and release of plasminogen activators, their inhibitors and receptor by human tumor cell lines.
abstract: Plasminogen activators (PAs) and their inhibitors (PAIs) can be produced by tumor cells and surrounding inflammatory cells and fibroblasts. The present study evaluate both the expression and release of PAs (uPA and tPA) and PAIs (PAI-1 and PAI-2) from cultured cells, and also the expression of uPA receptor (uPAR). Immunocytochemistry showed that PAs, PAIs and uPAR were present to different extents on the surface of colon carcinoma cells (Caco-2, HT-29), malignant melanoma cells (LOX) and normal fibroblasts. uPA immunoreactivity was intermediate in Caco-2, HT-29 and LOX and weak in the fibroblasts. tPA immunoreactivity was intermediate in Caco-2 and LOX and weak in HT-29 and fibroblasts. PAI-1 and PAI-2 immunoreactivities were absent in HT-29, weak in Caco-2 and strong in fibroblasts. In LOX the immunoreactivity was intermediate for PAI-1 and strong for PAI-2. uPAR immunoreactivity was weak in Caco-2, HT-29 and LOX and negative in fibroblasts. ELISAs on conditioned medium detected that the colon carcinoma cells Caco-2 and HT-29 did not release any PAs or PAIs. LOX released tPA (median 9 ng/million cells at 72 hours), PAI-1 (1050 ng/million cells) and PAI-2 (245 ng/million cells), and fibroblasts released uPA (1 ng/million cells) and PAI-1 (910 ng/million cells). These results show that both tumor cells and fibroblasts express tissue destructive enzymes, PAs and PAIs, whereas only the tumor cells express the uPAR required for focalization and regulation of PA activity at the cell surface. The melanoma cells LOX and fibroblasts also released PAs and PAIs, in contrast to the colon carcinoma cells Caco-2 and HT-29.
authors.affiliation: Institute for Surgical Research, Rikshospitalet Oslo, Norway.
authors.forename: L
authors.initials: L
authors.lastname: Buø
authors.forename: K
authors.initials: K
authors.lastname: Bjørnland
authors.forename: T S
authors.initials: TS
authors.lastname: Karlsrud
authors.forename: D
authors.initials: D
authors.lastname: Kvale
authors.forename: I
authors.initials: I
authors.lastname: Kjønniksen
authors.forename: O
authors.initials: O
authors.lastname: Fodstad
authors.forename: P
authors.initials: P
authors.lastname: Brandtzaeg
authors.forename: H T
authors.initials: HT
authors.lastname: Johansen
authors.forename: A O
authors.initials: AO
authors.lastname: Aasen
mesh_terms: D002460:Cell Line; D003110:Colonic Neoplasms; D017077:Culture Media, Conditioned; D005347:Fibroblasts / Q000378:metabolism; D015870:Gene Expression; D006801:Humans; D007150:Immunohistochemistry; D007700:Kinetics; D008545:Melanoma; D017395:Plasminogen Activator Inhibitor 1 / Q000096:biosynthesis*; D017396:Plasminogen Activator Inhibitor 2 / Q000096:biosynthesis*; D011956:Receptors, Cell Surface / Q000096:biosynthesis*; D055293:Receptors, Urokinase Plasminogen Activator; D012867:Skin; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000096:biosynthesis*; D014407:Tumor Cells, Cultured; D014568:Urokinase-Type Plasminogen Activator / Q000096:biosynthesis*
chemical_list: D017077:Culture Media, Conditioned; C524898:PLAUR protein, human; D017395:Plasminogen Activator Inhibitor 1; D017396:Plasminogen Activator Inhibitor 2; D011956:Receptors, Cell Surface; D055293:Receptors, Urokinase Plasminogen Activator; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator